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Background: The ACVR1 gene encodes a type I receptor for bone morphogenetic proteins (BMPs). Mutations in the
ACVR1 gene are associated with Fibrodysplasia Ossificans Progressiva (FOP), a rare and extremely disabling disorder
characterized by congenital malformation of the great toes and progressive heterotopic endochondral ossification
in muscles and other non-skeletal tissues. Several aspects of FOP pathophysiology are still poorly understood,
including mechanisms regulating ACVR1 expression. This work aimed to identify regulatory elements that control
ACVR1 gene transcription.
Methods and results: We first characterized the structure and composition of human ACVR1 gene transcripts by
identifying the transcription start site, and then characterized a 2.9 kb upstream region. This region showed strong
activating activity when tested by reporter gene assays in transfected cells. We identified specific elements within
the 2.9 kb region that are important for transcription factor binding using deletion constructs, co-transfection
experiments with plasmids expressing selected transcription factors, site-directed mutagenesis of consensus
binding-site sequences, and by protein/DNA binding assays. We also characterized a GC-rich minimal promoter
region containing binding sites for the Sp1 transcription factor.
Conclusions: Our results showed that several transcription factors such as Egr-1, Egr-2, ZBTB7A/LRF, and Hey1,
regulate the ACVR1 promoter by binding to the -762/-308 region, which is essential to confer maximal
transcriptional activity. The Sp1 transcription factor acts at the most proximal promoter segment upstream of the
transcription start site. We observed significant differences in different cell types suggesting tissue specificity of
transcriptional regulation. These findings provide novel insights into the molecular mechanisms that regulate
expression of the ACVR1 gene and that could be targets of new strategies for future therapeutic treatments.
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Fibrodysplasia Ossificans Progressiva (FOP, OMIM 135100)
is a rare and extremely disabling disorder characterized by
congenital malformation of the great toes and progressive
endochondral heterotopic ossification (HO) [1]. Its preva-
lence is approximately 1/2,000.000, without ethnic, racial,
gender or geographic predilection of disease. HO affects* Correspondence: bocciardi@unige.it
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reproduction in any medium, provided the orconnective tissues such as skeletal muscle, tendon, liga-
ments, fascia, and aponeuroses with an episodic postnatal
course characterized by flare-up and remission phases [1].
It is noteworthy to underscore that FOP flare-ups culminat-
ing in HO are frequently induced by soft tissue injury, such
as trauma, muscle fatigue, surgery, infections, intramuscu-
lar injections, preschool immunizations; in other cases,
FOP HO appears to initiate spontaneously without any ap-
parent trigger [1].
Histological analyses of early FOP lesions from patients
and animal models, show a first phase of strong local in-
flammation, with monocytes and lymphocytes infiltrationral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by a second phase characterized by a fibro-proliferative re-
sponse and angiogenesis, ending with the formation of ec-
topic, but otherwise qualitatively normal, bone [2-4]. This
evidence suggests that inflammation and immune medi-
ated mechanisms play a crucial role in FOP disease pro-
gression and that activation of inflammatory pathways
through the innate immune system could be relevant for
postnatal flare-ups [3].
The molecular defect responsible for FOP is a hetero-
zygous mutation in the ACVR1 gene encoding the ALK2
Activin A type I receptor, a receptor for bone morpho-
genetic proteins (BMPs) [5]. Although most cases are spor-
adic (de novo mutations), a small number of inherited FOP
cases show germline transmission in an autosomal domin-
ant pattern [5]. The mutation that causes FOP moderately
over-activates the BMP pathway in the absence of BMP
binding [6-10], yet allows human embryonic development
to occur relatively unimpaired with only mild skeletal ef-
fects, most typically malformation of great toes.
The majority of FOP patients are heterozygous for a
recurrent activating mutation (c.617G>A; p.R206H) in the
cytoplasmic GS (glycine-serine rich) domain of the recep-
tor protein, as first reported by Shore and colleagues [5].
Other less frequent heterozygous ACVR1 missense muta-
tions in highly conserved amino acids located near the GS
regulatory region or within the kinase domain, have also
been described [11-16].
A very critical and still poorly understood aspect of the
pathogenic mechanism of FOP is the nature of initial
stimuli that trigger flare-up episodes to result in subse-
quent ossification in patients with the gene mutation (see
reviews [2,3]). A plausible hypothesis is that the moderate
hyper-activity of BMP signaling caused by the mutated
receptor does not cause significant consequences under
basal in vivo conditions in connective tissues. However,
such a mutation would predispose the cells to respond to
changes in the local tissue environment, such as inflam-
matory processes after tissue injury or other stimuli, by
forming extra-skeletal bone. This hypothesis is consistent
with quiescent periods that are observed in patients be-
tween active episodes of heterotopic bone formation.
Up to now, no effective and specific treatment is avail-
able and the only prevention is prophylactic measures
against falls, infections, and soft tissue injuries [1]. The
discovery of mutations in the ACVR1 gene has opened
the way to identify and characterize cellular and molecu-
lar mechanisms that can become targets for therapeutic
control of heterotopic ossification in FOP.
While numerous articles and reviews about FOP and
the BMP signaling pathway have been published, our
knowledge of how ACVR1 is regulated at different levels
and how ACVR1 transcription responds to changing
cell environments under developmental, physiological orpathological conditions is still limited. For this reason, we
conducted a characterization of the genomic region con-
taining the ACVR1 gene promoter in order to identify
mechanisms and factors that regulate its expression at the
transcriptional level. A previously published article de-
scribed a regulatory region located upstream of the ATG
start codon that was defined as the ACVR1-ALK2 pro-
moter by the authors [17]. However, the study did not
consider the extended 5’UTR region shown in GenBank
annotations for the ACVR1 gene. This extended 5’UTR in-
cludes untranslated exons and long intronic sequences
that predict a gene promoter region at ~78 kb upstream
of the sequences described by Yao and coworkers [17].
In this study, we describe the characterization of a 2.9
kb ACVR1 promoter region with respect to its transcrip-
tional start site and show that a number of transcription
factors play an important role in regulating ACVR1 tran-
scription. These data have potential to inform future stud-
ies regarding the regulation and function of the ACVR1
gene in various processes as well as providing novel tar-
gets for future therapeutic approaches for FOP disease.
Materials and methods
Reagents, vectors and antibodies
Human recombinant BMP2 was purchased from R&D
Systems (Minneapolis, MN). The following constructs were
obtained as kind gifts from the indicated person/group:
IdI-BMP-Responsive Element/Luciferase expression vector
(BRE-Luc) from Dr Peter Ten Dijke; pCMV-Sp1 from Dr
Francesco Ramirez; Egr-2 from Dr Marco Musso and Egr-1
from Dr Patrick Charnay. Expression vectors carrying the
cDNA of Hey1 (isoform 1, v1, RefSeq NM_012258.2, SC1
15467; and isoform 2, v2, RefSeq NM_00104070.1, SC3
11179) and ZBTB7A (RefSeq NM_015898.2, SC114581)
transcription factors were purchased from OriGene (True
Clone, OriGene Technology, Inc., Rockville, MD) as ready-
to-transfect DNA.
Antibodies directed against Sp-1 (sc-59), Egr-1 (sc-189)
and Egr-2 (sc-20690 and sc-20450) were obtained from
Santa Cruz Biotechnology Inc.
Bioinformatic analysis
Bioinformatic analysis of the genomic region at the 5'
end of the ACVR1 gene was performed using web-based
software programs. Information on ESTs, positions of con-
served binding sites for transcription factors, and data from
the ENCODE project were obtained from the correspond-
ing tracks of the UCSC Genome Browser in a window
spanning a 2913 bp genomic region (chr2:158,732,343-
158,735,255, UCSC Genome Browser, Feb2009 GRCh37/
hg19 Assembly). Analysis of the GC nucleotide content
used the CpG-plot tool at the EMBL-EBI European Bio-
informatics Institute, [http://www.ebi.ac.uk/Tools/emboss/
cpgplot].
Table 2 Names and sequences of the oligonucleoides
used in the present work
Name Sequence of oligonucleotides used in this work
LTR-1F CAAGTACTGTTACAGGACCC
Sph-1F TGCTCCCACCTACTCCATCC
Prom-3Frev GCCATGGGAGCTTACAGTG
067-F/REV GAGGCGGAGTGCGAGGCAGC
6R CGAAGGCAGCTAACTGTATC
1.2-F (AGCTGGTACC)AGCCCCTCCATGCTTATTTC
0.7-F (AGCTGGTACC)GCTCATAGCTTCCAC
0.6-F (AGCTGGTACC)GGAGGAAATGATGTGTTGCTG
0.3-F (AGCTGGTACC)GAAGTTTATTCTGCCC
0.16-F (AGCTGGTACC)GCTGCAGCCACCGCAG
0.072-F (AGCTGGTACC)CCGCAGAGTTCC
Oligonucleotides for site-directed mutagenesis
Fr072mut-F CACCGCCCCGAACCGAACCGCGCCGAACCGCGCCGCG
Fr072mut-R CGCGGCGCGGTTCGGCGCGGTTCGGTTCGGGGCGGTG
Oligonucleotides for EMSA
GC-emsa F GCCCCGCCCCGCCCCGCGCCGCCCCGCG
GC-emsa R GGCGCGGGGCGGCGCGGGGCGGGGCGGGG
GCmut-emsa F GCCCCGAACCGAACCGCGCCGAACCGCG
GCmut-emsa R GGCGCGGTTCGGCGCGGTTCGGTTCGGGG
(agctggtacc) Extrabases and Kpn-1 recognition site (italic) to facilitate PCR
products subcloning in the pGL3-basic Luciferase expression vector.
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for comparative genomics of the VISTA Genome Browser
http://pipeline.lbl.gov/cgi-bin/gateway2. The search for
transcription factor binding sites in selected regions, was
performed with MatInspector software [http://www.geno
matix.de/solutions/genomatix-software-suite.html] [18].
Plasmid construction
The 2.9 kb genomic segment of the ACVR1 promoter was
reconstructed from two partially overlapping PCR frag-
ments generated with LTR-1F + Prom-3Frev (fragment 1)
and Sph-1F067-F/Rev (fragment 2) oligonucleotide cou-
ples, and the PCR Extender Polymerase Mix (5Prime)
using the protocol for GC-rich templates suggested by the
manufacturer. The two fragments were subcloned into the
pCR2.1 vector (TOPO-TA cloning kit, Invitrogen), and
orientation of the inserts was checked by restriction di-
gests. Insert 2, obtained by double restriction with Kpn-1
(present in the multiple cloning site of the pCR2.1 vector)
and Bgl-II (unique restriction site present in the region of
overlap between the two PCR fragments), was then in-
serted into the intermediate pCR2.1-fragment 1 plasmid
prepared with same double restriction. Finally, the re-
sulting complete 2.9 kb insert was subcloned in the Kpn-I
site of the pGL3-Basic expression vector (Promega). This
plasmid construct was also used as a template in PCR re-
actions designed to obtain fragments of the promoter pro-
gressively deleted at the 5' end, by combining specific
forward oligonucleotides with a common reverse primer
mapping at the beginning of the first 5'UTR ACVR1 exon
(see Table 1, for position, length and oligonucleotides used
to generate the corresponding fragment; see Table 2 for ol-
igonucleotides sequences). All the constructs were checked
by restriction enzyme digestion and direct sequencing ac-
cording to standard protocols.
RNA extraction and cDNA synthesis
Total RNA was extracted from cells using the RNeasy
Mini Kit from Qiagen. RNA quantity was measured withTable 1 List of the reporter constructs used in this work
Construct Insert
length
(bp)
Position on chr2
(UCSC Feb2009/
GRCh37/hg19)
Name of
oligonucleotides
used
pPrACVR1-2.9 2913 158,732,343-158,735,255 see text
pPrACVR1-1.4 1420 158,732,343-158,733,762 see text
pPrACVR1-1.2 1190 158,732,343-158,733,532 1.2-F+067-F/r
pPrACVR1-0.7 794 158,732,343-158,733,136 0.7-F+067-F/r
pPrACVR1-0.6 613 158,732,343-158,732,955 0.6-F+067-F/r
pPrACVR1-0.3 339 158,732,343-158,732,681 0.3-F+067-F/r
pPrACVR1-0.16 163 158,732,343-158,732,505 0.16-F+067-F/r
pPrACVR1-0.072 104 158,732,343-158,732,446 0.072-F+067-F/rNanodrop Spectrophotometer (Thermoscientific), and first
strand cDNA was synthesized from 200 ng of total RNA
with the Advantage RT-for-PCR Kit (Becton Dickinson)
according to the manufacturer's protocol.Quantitative reverse transcription PCR (RT-qPCR)
Expression of the endogenous ACVR1 gene was evalu-
ated by RT-qPCR using specific TaqMan Gene Expres-
sion Assay (Applied Biosystems) (Table 3). Samples were
measured in triplicate and the data were normalizedTable 3 List of the probes for RT-qPCR experiments used
in this work
Gene TaqMan Gene Expression Assay
(Species and ID specification)
ACVR1/Alk2 Homo sapiens Hs00153836_m1
acvr1/alk2 Mus musculus Mm00431645_m1
β-Actin Homo sapiens Hs99999903_m1
β-Actin Mus musculus Mm00607939_1
GADPH Homo sapiens Hs99999905_m1
gadph Mus musculus Mm99999915_g1
β2-Microglobulin Homo sapiens Hs99999907_m1
β2-microglobulin Mus musculus Mm00437762_m1
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Microglobulin, depending on the cell line. qPCR data
(generated using a BioRad IQ5 instrument) was analyzed
with Bio-Rad iQ5 software for Gene Expression studies.
Under the experimental conditions used, no effect of
mithramycin treatment on expression of the references
genes was observed.
Cell culture and transfection
U2OS, HeLa, and C2C12 cells were from ATCC (ATCC-
LGC Standards Partnership). ATDC5 cells were obtained
from the Cell Bank of the Riken Bioresource Center, Japan.
Cells were cultured as follows: C2C12 (mouse myoblast
cells) in α-minimal essential medium (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS, Invitrogen);
U2OS (human osteosarcoma cells) cells in McCoy's 5a
Medium (Invitrogen) supplemented with 10% FBS; HeLa
cells in Eagle's Minimum Essential Medium (Invitrogen)
supplemented with 10% FBS; ATDC5 (mouse chondrogenic
cell line derived from teratocarcinoma) cells in DMEM:
Ham's F12 (1:1) (Invitrogen) with 5% FBS. All culture media
were supplemented with 2 mM glutamine and 100U/ml
penicillin and 100 μg/ml streptomycin and cells were grown
in a humidified atmosphere with 5% CO2.
For transfection experiments, cells were plated at
25000-30000 cells/well in 24-well plates in the cell complete
medium for one day then transfected with Lipofectamine
2000 (Invitrogen).
Briefly, the transfection mixtures contained 50 μl Opti
MEM (Invitrogen), 2 μl Lipofectamine 2000, 25 ng pRL-
TK-Renilla (Promega) as a control of transfection efficiency,
400 ng promoter-Luciferase constructs and, as indicated,
400 ng of a specific transcription factor expression vector
or empty vector as control. 24 hours after transfection, cells
were lysed with 100 μl Passive Lysis Buffer (Promega) for
20 min and 20 μl of the obtained lysate was used to mea-
sure Luciferase activity with the Dual-Luciferase Assay
kit (Dual-Luciferase® Reporter Assay System, Promega)
according to the manufacturer's procedure. Luciferase ac-
tivity was quantified using the GLOMAX Multi Detection
System (Promega).
As indicated, 24 hrs after transfection, cells were cul-
tured in depletion medium (without FBS and in presence
of 0.1% BSA) and treated overnight with 100 ng/ml BMP2
(R&D Systems) or mithramcycin at 200 or 300 nM. The
impact of mithramycin treatment on cell viability was eval-
uated by a fluorescence-based viability assay (CellTiter-
Fluor™Cell Viability Assay, Promega) and no significant
effect was found upon the experimental conditions used.
Preparation of nuclear extracts and electrophoretic
mobility shift assay (EMSA)
Nuclear extracts were prepared from subconfluent HeLa
cells. Cells were washed with PBS then detached with PBS/1 mM EDTA, pelleted, washed once with PBS, resuspended
in 5 packed cell volumes of hypotonic buffer (10 mM
Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT,
0.5 mM phenylmethylsulfonyl fluoride), and incubated for
10 min on ice. After centrifugation at 4°C, the cells were
resuspended in 3 packed-cell volumes of the same buffer
containing 0.05% Nonidet P-40 (NP-40) and Dounce
homogenized. The nuclei were collected by low speed
centrifugation at 400 g for 10 min, then washed once
with the same buffer described above, without NP-40,
and resuspended in high salt buffer (5 mM Hepes, pH 7.9,
26% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 420 mM
NaCl, 0.5 mM DTT, 0.5 mM phenylmethylsulfonylfluoride),
incubated at 4°C for 30–60 min, and centrifuged at
21,000 g at 4°C for 40 min. The supernatant was aliquoted
and stored at -70°C; protein content was evaluated by
Bradford assay.
EMSA was performed as previously described [19].
Briefly, double-stranded oligonucleotides were labeled by
filling-in the 5' ends with 3000 Ci/mmol [a-32P]dCTP
and purified on G-25 Sephadex column (Roche Applied
Science). All probes were 100% labeled. Reactions con-
taining 5 μg of nuclear extract, 10 μl of 2X binding buf-
fer (1X binding buffer: 20 mM Hepes, pH 7.9, 2 mM
MgCl2, 4% Ficoll, 0.5 mM DTT), 2 μg of double-stranded
poly(dI-dC) (Sigma-Aldrich, St.Louis, MO, USA), 100 mM
final salt concentration (NaCl + KCl) were assembled in a
final volume of 20 μl and preincubated for 30 min on ice;
10,000–20,000 cpm of the labeled probes (corresponding
to 2 fmol) were added to each reaction. After 30 min on
ice, the reactions were electrophoresed through TBE, 5%
non-denaturing polyacrylamide gels at a constant voltage
of 150 V. Competition experiments and supershifts used
reactions preincubated with the appropriate amounts of
cold oligonucleotide and antibody (anti-SP1, Upstate,
Charlottesville, VA and Santa Cruz Biotechnology). The ol-
igonucleotides used for EMSA are reported in Table 2.
The Sp1 and EGR oligonucleotides were described previ-
ously [19]. All oligonucleotides were synthesized by TIB
MolBiol (Roche).Statistical analysis
All luciferase reporter gene assays using the ACVR1
promoter constructs were performed in triplicate and
repeated independently at least twice (2-5 times). Exper-
iments to evaluate ACVR1 expression by RT-qPCR were
perfomed in triplicate from at least two independent
RNA extractions.
As indicated, the non-parametric Mann–Whitney Test
(GraphPad InSTAT package) was applied to verify statis-
tical significance of the observed variations, significant
differences were given as p < 0.05*, p < 0.01**, or
p < 0.001***.
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Characterization of the ACVR1 promoter
To identify and characterize the ACVR1 promoter se-
quence and RNA transcriptional start site, we conducted
both a bioinformatic analysis of the genomic region lo-
cated 5' upstream of the gene and an experimental ap-
proach through 5'RACE. Current GenBank annotation
reports two different mRNA RefSeq (NM_001111067.2
and NM_001105.4) that consist of two untranslated exons
preceding nine protein-coding exons. According to these
observations, putative alternative 5'UTR sequences are
combined to common protein-coding sequences that initi-
ate in the third exon and extend over nine exons. 5'RACE
experiments using cDNA from adult brain detected an
ACVR1 transcription start site (TSS) mapping between
244 and 237 bp upstream of the ATG starting codon rela-
tive to the NM_001111067.2 RefSeq (not shown). This
TSS corresponds to the start of the most upstream un-
translated exon, possibly representing the most abundant
transcript in the analyzed tissue and differing in only five
base pairs compared to GenBank NM_001111067.2.
Therefore, we started our experimental analysis by
focusing on the genomic sequence upstream of this pos-
ition and spanning around 2.9 kb (chr2:158,732,343-158,
735,255, UCSC Genome Browser, Human Feb. 2009 (GR
Ch37/hg19)).
This region has 55% of GC nucleotides clustered in
long stretches predominantly mapping to the proximal
1 kb segment, as indicated in the GC-plot reported
in Figure 1A. No TATA-boxes are present. The region
appeared well-conserved in mouse as shown by compa-
rison analysis performed at the Vista Genome Browser
(Figure 1B).
The entire 2.9 kb sequence was subcloned into the
pGL3-basic Luciferase expression vector to generate the
pPr-2.9 construct (Figure 2A). In order to determine
whether this fragment was able to drive the expression
of the Luciferase reporter gene, the plasmid was trans-
fected into different cell lines (U2OS, HeLa, C2C12 and
ATDC5). As shown in Figure 2B, this construct had strong
promoter activity as compared to cells with the pGL3-
Promoter vector carrying the SV40 promoter sequence.
The level of transcriptional activity was different in the
various cell lines, with the strongest activity in U2OS cells
and the lowest in C2C12. In accordance, we found that the
level of mRNA expressed from the endogenous ACVR1
gene in U2OS and HeLa cells was proportional to pro-
moter activity (Figure 2C).
Deletion constructs of the 2.9 kb region were generated
in order to more specifically identify regulatory elements.
Deletion regions were selected based on the human/mouse
conservation profile, the presence of GC-clusters, and puta-
tive recognition sites for transcription factors, and the dele-
tion constructs are schematically represented in Figure 3A.All the generated constructs were transfected into
multiple cell lines and their respective transcriptional ac-
tivities are shown in Figure 3B relative to the activity
driven by the pPr-2.9 plasmid containing the entire pro-
moter region. The two longest deletion constructs (pPr-
1.4 and pPr-1.2) showed similar promoter activity as the
2.9 kb fragment (pPr-2.9). Deletion of the region be-
tween position -1157 and -762 led to limited increase of
the transcriptional activity, probably because of the removal
of negative cis-acting elements functional in U2OS, HeLa
and C2C12 cells. Deletion of the region between -762 and -
308 caused a decrease in transcriptional activity in all the
tested cell lines, suggesting the presence of functional
elements important for promoter activity. The smallest
pPr-0.3 construct still showed a clearly detectable activity.
The pattern of transcriptional activity driven by the deletion
constructs was similar in all the tested cell lines.
Effects of Egr-1, Hey-1 and ZBTB7A/LRF/pokemon on
ACVR1 transcription
The observation that deletion of the genomic region com-
prised between -762 and -308 resulted in a strong reduc-
tion of the transcriptional activity driven by the ACVR1
promoter, induced us to focus our functional analysis on
this sequence.
Data obtained through the ENCODE Project (En-
cyclopedia of DNA Elements) provides experimental
ChIP-seq (deep sequencing after Chromatin Immuno-
Precipitation) evidence of transcription factor binding
at the genome-wide level. ENCODE data for the 2.9 kb
region of the ACVR1 promoter provided evidence of tran-
scription factor binding, as shown in Additional file 1:
Figure S1 (ENCODE data [20]). We selected some of
these transcription factors for further ACVR1 functional
analysis based on their reported involvement in osteogenic
processes [21-23], immune-mediated mechanisms [24-26],
and cross talk among important pathways [27-29].
Egr-1, Hey-1, and ZBTB7A cDNA expression vectors
were co-transfected with the reporter constructs of se-
lected deletion fragments of the ACVR1 promoter (pPr-
2.9, pPr-0.7 and pPr-0.3) into HeLa and ATDC5 cells
representing, respectively, cell types not related and related
to chondrogenesis/osteogenesis. Our results showed that
the effect of these factors was dependent on cell type, at
least for Egr-1 and ZBTB7A. As shown in Figure 4A, in
HeLa cells both Egr-1 and ZBTB7A induced a strong acti-
vating effect on the transcriptional activity of the 2.9 kb
ACVR1 promoter. For Egr-1, the effect was progressively
reduced with deletion constructs (Figure 4A, left panel),
whereas ZBTB7A still exerted a stimulatory effect also on
the smallest pPr-0.3 fragment. Consistently, the evidence
provided by the ENCODE project indicates that binding
sites for ZBTB7A are present in the genomic region con-
tained in this short construct. However, in ATDC5 cells,
Figure 1 Base composition and conservation of the human ACVR1 promoter. A) CpG islands plot reporting the analysis of the
GC-nucleotide content and structure of the ACVR1 2.9 kb genomic region upstream of the TSS using the CpG-plot tool at the EMBL-EBI European
Bioinformatics Institut, [http://www.ebi.ac.uk/Tools/emboss/cpgplot]. Upper panel: plot of the ratio of the observed over the expected GC content.
Middle panel: GC content expressed as percentage (minimum percentage required to identify the presence of a CpG islands is 50%). Lower
panel: identification of a 975 bp CpG island upstream and proximal to the first 5'UTR exon of the ACVR1 gene. B) Output of the comparative
genomic analysis obtained with dedicated software available at the Vista Genome Browser (http://genome.lbl.gov/vista/index.shtml, tools for
comparative analysis). Conserved sequences with a percentage of identity (vertical axis) that is higher than 70% are represented as red peaks
(non coding sequences) and light blue peaks (UTR sequences, corresponding to the first UTR exon of the ACVR1 gene according to the
NM_001111067.2 RefSeq) and are shown relative to their position in the human genome (horizontal axis) compared to the mouse.
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by the whole ACVR1 promoter and by the 700 bp-
containing deletion construct. Interestingly, in these cells,
ZBTB7A showed an inhibitory effect on the function of
the smallest fragment tested (Figure 4B, left panel).
By contrast to Egr-1 and ZBTB7A, expression of both
Hey-1 isoforms induced a decrease in the transcriptional
activity driven by the ACVR1 promoter (Figure 4, right
panels), in both HeLa and ATDC5 cell lines, although with
some quantitative differences between the two cell types.
This effect was observed for all three promoter segments,
as we might expect from the presence of binding sites inthe -762/-308 region and also in the most proximal se-
quence of the promoter (Additional file 1: Figure S1).
Characterization of a basal promoter region
As indicated above, the ACVR1 promoter sequence does
not contain a TATA box and is GC-rich, suggesting that the
region proximal to the TSS might function as a basal pro-
moter. To identify the region necessary for basal transcrip-
tion of ACVR1, two additional deletion constructs were
generated (see Figure 3A for a schematic representation of
the constructs), pPr-0.16 and pPr-0.072, containing only
160 or 72 bp upstream of the TSS, respectively.
Figure 2 Transcriptional activity of the 2.9 kb promoter region of human ACVR1 gene in different cell lines. A) Schematic representation
of the ACVR1 genomic structure and of the reporter construct containing the 2.9 kb genomic fragment. The gene consists of eleven exons, two
untranslated (grey rectangles) and nine protein coding exons (black rectangles). The 2.9 region upstream the TSS indicated as +1 was subcloned
upstream the Luciferase coding sequence as described in the Materials and Methods (this reporter construct is referred as Pr-2.9). B) Results
obtained by transient transfection of the Pr-2.9 construct in the indicated cell lines. Transcriptional activity is reported as relative to the activity of
the pGL3-Promoter vector carrying the SV40 promoter as control (Ref Act, 100%, RLU, Relative Light Unit). C) mRNA levels of the endogenous
ACVR1 gene as assessed by RT-qPCR in U2OS and HeLa cells. GAPDH and β2-Microglobulin were used as Reference genes.
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bp up to -72 bp, transcriptional activity was maintained in
all transfected cell lines, although with quantitative differ-
ences. Nevertheless, the residual activity driven by the
smallest fragment (pPr-0.072) was still significant, ranging
from 6% to 20% depending on the cell lines used (Figure 5).
Therefore, we have defined this 72 bp region as the basal
promoter of the ACVR1 gene. The region contains 87.5%
GC (63 GC nucleotides out of 72) that are organized in
overlapping GC-boxes (Figure 6A). This feature is a com-
mon finding in TATA-less gene promoters, and these se-
quence elements are likely to function as docking sites for
GC-binding proteins.
An in silico search for transcription factors binding
sites revealed that the region contains a well-conserved
putative recognition site for the Sp1 transcription factor
(Figure 6B), an established GC-binding protein able to
regulate both basal and induced gene transcription work-
ing alone, or by recruiting other transcription factors (for
a review see [30]).
We tested whether the Sp1 protein could influence the
transcriptional activity driven by the 72 bp basal region
by performing site-directed mutagenesis to destroy the
overlapping GC boxes predicted to bind the protein
(Figure 6A and 6B). As reported in Figure 6C, site-directed mutagenesis altering the GC-boxes affected the
transcriptional activity of the ACVR1 basal promoter in
HeLa (reduced to 57% of the WT activity) and in C2C12
cells (29% of the WT activity) (Figure 6C). The effect was
less evident in U2OS cells (86% of activity was maintained)
and no effect was detectable in ATDC5 cells (Figure 6C).
We then co-transfected cells with the pPr-0.072 construct
(wild type or mutant) and an expression vector carrying the
Sp1 cDNA (pCMV-Sp1) or the corresponding CMV empty
vector as a control. Over-expression of Sp1 increased the
transcriptional activity of the basal promoter, although to
different levels in the various cell lines (Figure 6D). This in-
duction was impaired by mutagenesis of the GC-boxes, ex-
cept for the ATDC5 cell line.
Consistently, treatment of U2OS and C2C12 cells with
mithramycin A, an antibiotic frequently used as an Sp1
inhibitor [31], led to a dose-dependent decrease in the
expression of endogenous ACVR1 gene, as assessed by
RT-qPCR in the U2OS and C2C12 cell lines (Additional
file 2: Figure S2, supplementary material). To complete
our analysis on the involvement of the Sp1 transcription
factor in ACVR1 basal promoter regulation, we carried
out an Electrophoretic Mobility Shift Assay (EMSA) by
using a 30 bp double-stranded probe overlapping the
GC boxes with nuclear extracts from different cell lines.
Figure 3 Functional characterization of the 2.9 kb promoter region of human ACVR1 gene. A) Schematic representation of the deletion
constructs derived from the ACVR1 2.9 kb promoter region. These reporter constructs were transiently transfected in U2OS (B), HeLa (C), C2C12
(D) and ATDC5 cells (E), together with the pRL-TK-Renilla plasmid as a control for transfection efficiency. The corresponding observed activities
are shown as relative to the activity of the Pr-2.9 ACVR1 promoter construct (100%). The data represent the mean ± SD (error bars) of five
independent experiments conducted in triplicate, with p < 0.05*, p < 0.01**, or p < 0.001*** comparing the activity of each deletion construct with
the 2.9 kb promoter.
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are shown. Specific DNA/Sp1 protein complexes were
detected (Figure 7, arrows) which were efficiently com-
peted by the unlabeled probe (Figure 7, +WT comp), but
not by a cold probe carrying the same mutated residues
as in the transfected constructs (+Mut comp). Moreover,
the observed complexes were further shifted by the pres-
ence of antibodies against Sp1, thus identifying Sp1 asable to bind sequences in this genomic region (Figure 7,
asterisk).
Besides Sp1, other factors such as Egr-1 and 2 proteins
are known to bind GC-rich recognition sequences. We
co-transfected cells with the pPr-0.072 wild-type and ex-
pression vectors carrying the Egr-1 or Egr-2 cDNAs or
the corresponding empty vector. As shown in Additional
file 3: Figure S3, Egr-1 expression induced a decrease in
Figure 4 Effects of Egr-1, Hey-1 and ZBTB7A/LRF/pokemon on ACVR1 promoter activity. Expression vectors carrying the cDNA of Egr-1,
Hey-1 or ZBTB7A/LRF/pokemon transcription factors were transiently transfected in the HeLa (A) and ATDC5 (B) cell lines together with the three
reporter ACVR1 promoter deletion constructs (Pr-2.9, Pr-0.7 and Pr-0.3) and the pRL-TK-Renilla plasmid as control for transfection efficiency.
Detected activities are expressed relative to those of the same promoter construct co-transfected with empty expression vector considered as
100% (RLU, Relative Light Unit). The data represent the mean ± SD (error bars) of independent experiments (n=2 in HeLa cells, n=3 in ATDC5
cells) carried out in triplicate with p < 0.05*, p < 0.01**, or p < 0.001***. ev, empty vector, corresponding to the empty expression plasmid of the
selected transcription factors. For the Hey-1 protein, two different cDNAs corresponding to two isoforms (indicated as v1 and v2) differing by four
residues in the HLH domain were used.
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and ATDC5 cells at comparable levels. No effect was ob-
served in HeLa cells. Interestingly, a more cell type-
dependent effect was detectable upon expression of Egr-2
proteins. As reported in Additional file 3: Figure S3, no or
little effect was observed in U2OS, whereas a clear activat-
ing effect was observed in the other cell lines, particularly
evident in HeLa and C2C12.
An additional regulatory element, one that would be
particularly important in the promoter of a gene encoding
a BMP receptor, is the BMP Responsive Element (BRE)
[32]. Although in silico search for such element did not
predict its presence in the above mentioned promoter seg-
ment, these regulatory elements are characterized by a
GC-rich sequence. Therefore, we wanted to verify if the
Luciferase construct with the 72 bp basal promoter se-
quence is responsive to BMP ligands. Transfection experi-
ments in HeLa and C2C12 cells treated with BMP2
(Figure 8) showed no effect on the 72 bp promoter region
in both cell types. However, the constructs containing the
2.9 kb region were responsive to BMP2 treatment in
C2C12 cells, although not in HeLa. We also observed an
increase in ACVR1 mRNA in C2C12 cells after treatment
with BMP2. In agreement with the experimental data, insilico analysis predicts the presence of two BRE elements
in the distal half of the gene (position -1188/-1183 and
-657/-652, respectively).
Discussion
In the present study, we provided the first charac-
terization of the ACVR1 gene promoter region. This
gene is mutated in patients affected by FOP, causing a
hyper-activation of the BMP SMAD-dependent signaling
pathway. The pathogenic events resulting in heterotopic
ossification in FOP are associated with mechanisms re-
lated to inflammatory stimuli that trigger osteogenic dif-
ferentiation in pluripotent progenitors in postnatal life.
It is conceivable that these mechanisms could be targeted
to some levels of BMP signaling pathways thus providing
strategies to control the most devastating effects of this
genetically-based disorder in extra-skeletal tissues.
The discovery of ACVR1 as the gene responsible for
FOP has opened the way to treatment discovery efforts,
considering that the identification of a molecular target
related to the disease is the very first step of a drug devel-
opment process. Elements and factors controlling regula-
tion of gene and protein expression can be considered as
"sensitive nodes" (as defined in [33]) and thus may become
Figure 5 Identification of the basal promoter. Deletion constructs Pr-0.3, Pr-0.16, Pr-0.072 schematically represented in Figure 3A were
transiently transfected into U2OS (A), HeLa (B), C2C12 (C), ATDC5 (D) to characterize the basal promoter region. Results are expressed as relative
to the activity of the pGL3-Promoter vector carrying the SV40 promoter region (PV, 100%). The data represent the mean ± SD (error bars) of
independent experiments (3≥ n ≥ 5) carried out in triplicate with p < 0.05*, p < 0.01**, or p < 0.001***. comparing the activity of each deletion
construct with that of the SV40 promoter (PV).
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sidered that research on transcriptional mechanisms con-
trolling expression of the ACVR1 gene expression might
provide significant contributions to identifying sensitive
molecular targets.
To our knowledge, no previous characterization of the
ACVR1 promoter has been described and little informa-
tion about the transcriptional regulation of the gene has
been generated, with the exception of a study reporting
a regulatory element upstream of the translation initi-
ation codon [17]. ACVR1 has a transcribed and untrans-
lated region 5' to the translational start site that is quite
complicated in term of untranslated exons and alterna-
tive splicing (unpublished observations and GenBank an-
notations). Thus a first requirement was to identify a
TSS by 5'RACE experiments; we identified a major TSS
that is located at the 5'end of the first untranslated exon,
at least for the cells utilized for mRNA extraction. Given
the predicted complexity of the ACVR1 5'UTR, this result,
although confirming the presence of a TSS starting up-
stream of UTR exons, does not exclude other alternative
TSSs that might represent low abundance transcripts ortranscripts with cell type specificity different from the site
we have identified.
This result allowed us to explore the sequence up-
stream of the identified TSS for base composition, conser-
vation across species, and putative transcription factor
binding sites.
We cloned a region from -2900 bp to +35 relative to the
TSS (considered as the +1 nucleotide), into a Luciferase
expression reporter plasmid. This region showed a robust
ability to drive reporter vector expression, suggesting that
it represents the gene transcriptional regulatory region.
One first observation was differences in activity in various
cell lines, with the highest activity in U2OS osteosarcoma
cells, consistent with a high expression of ACVR1 mRNA
in this cell line, and suggesting the presence of factors that
target the regulatory sequence in optimal condition com-
pared to other cell types. Other cell types, however, are
also active in regulating the ACVR1 promoter relative to
the reference activity of the SV40 promoter in the pGL3-
Promoter vector.
The analysis of deletion constructs revealed the presence
of positive and negative regulatory elements. Removal of
Figure 6 Role of Sp1 in ACVR1 gene promoter regulation. A) Nucleotide sequence of the basal promoter of the ACVR1 gene lacks TATA
boxes and has high GC-nucleotide content. The putative Sp1 binding sites are indicated by boxes and nucleotides subjected to site-directed
mutagenesis are indicated with red circles. The arrow indicates the TSS (+1). B) In silico analysis of the region as it appears in the HMR Conserved
Transcription Factor Binding Sites (TFBS conserved) track in the UCSC Genome Browser revealed a well-conserved putative recognition site for the
Sp1 transcription factor. Custom tracks indicating the overlapping GC-boxes (ACVR1_Basal_Promoter_GC-Boxes) and the position of the
mutagenized nucleotides (GC-boxes_mutagenesis) were added to the UCSC window and are shown. C) Both the wild-type (WT) and mutated Pr-
0.072 constructs containing the 72 bp promoter region were transiently transfected into U2OS, HeLa, ATDC5, and C2C12 cell lines. Luciferase
activities obtained with mutated constructs are expressed as a percentage of the activity of the wild-type (100%) in each cell line. D) The effect of
Sp1 on basal promoter activity was tested by co-transfecting the Sp1 expression plasmid with the wild-type (WT) and mutated Pr-0.072 reporter
constructs in the indicated cell lines. Luciferase activity is expressed as relative to the transcriptional activity of the Pr-0.072WT in cells transfected
with the empty vector that was used to subclone the Sp1 cDNA (ev). The data represent the mean ± SD (error bars) of independent experiments
(n=5 for C, n=3 for D) carried out in triplicate with p< 0.05*, p< 0.01**, or p< 0.001***.
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Figure 7 Analysis of Sp1 binding to the ACVR1 72-bp promoter region. The Sp1 transcription factor binds the ACVR1 basal promoter as
assessed by EMSA experiments with HeLa nuclear extracts and a double-stranded probe spanning the GC-boxes contained in the fragment
(position -38 to -9). Lane 1, Free probe; lane 2, probe incubated with HeLa nuclear extracts (NE); lanes 3 to 5, DNA-protein complexes (arrows)
competed with the cold wild-type probe (50-, 100-, or 200-fold molar excess, respectively); lanes 4 to 8, DNA-protein complexes competed with
the cold mutated probe (50-, 100-, or 200-fold molar excess, respectively); lanes 9 and 10, DNA-proteins complexes incubated with probes
containing canonical consensus sites for Sp1 and Egr-family factors respectively; lanes 11 to 13, super-shift analyses of the DNA-protein complexes
with three different specific antibodies against Sp1. *, retarded complexes recognized by anti-Sp1 antibodies.
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effects among cell types, such as significant reduction of
activity in HeLa cells, that deserves further analysis for
more detailed interpretation. In the case of ATDC5 and
C2C12 cells, two cell types that are able to differentiate to
chondrocytes and osteoblasts, respectively, in appropriate
culture conditions, we observed differences in ACVR1 ex-
pression levels that we interpret as referable to subtle and
unintentional differences in standard culture conditions.
The most evident change, observed in all cell lines,
was decreased activity upon deletion of the sequence be-
tween -762 and -308 bp. This region is characterized by
a high degree of conservation and a number of binding
sites for several transcription factors that were detected
by ENCODE [20,34]. Our initial characterization of the
effect of some of these transcription factors focused on
those with possible implications for a FOP pathogenicmechanism. Their effect on the different promoter/re-
porter vectors varies according to the presence of puta-
tive binding sites in one or more than one position
within the 2.9 kb region and also according to the cell
type in which transfection experiments were performed.
The most consistent effect was by Hey-1 which showed
inhibitory effects on promoter regions where E-box bind-
ing sites were predicted, i.e., in the region between -762
and -308 and in the basal 72 bp region immediately up-
stream of the TSS. The Hey-1 transcription factor is a
member of the basic helix-loop-helix (bHLH) protein fam-
ily and a known target of the Notch1 signaling pathway
[27]. Interestingly, its expression is also regulated by
SMAD-dependent BMP signaling that suggests involve-
ment in cross-talk between these two important pathways
[28,29]. Cross-talk is made more interesting by the ob-
servation that its effect on ACVR1 expression could
Figure 8 Effect of BMP2 on ACVR1 promoter activity. A) HeLa and C2C12 cells were transfected with Pr-2.9 and Pr-0.072 reporter constructs and
Luciferase expression was determined in the presence or absence of 100 ng/ml BMP2. Results are expressed as fold activation relative to the activity by
the same promoter construct in absence of BMP2 (UN, untreated), with p< 0.05*, p< 0.01**, or p< 0.001***. B) ACVR1 mRNA expression levels were
detected by RT-qPCR in C2C12 cells upon treatment with BMP2. Values were normalized to the expression level of GAPDH and β-Actin genes.
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mechanism that acts on BMP signaling. The results of our
co-transfection experiments are in agreement with several
findings that support transcriptional inhibition of several
target genes by Hey transcription factors [35].
Members of the "Early Growth Response" (Egr) family
of transcription factors regulate gene transcription affect-
ing a wide range of processes including differentiation,
proliferation, and response to extracellular signals with cell
type- and context-specific characteristics (see in [24]). The
Egr-1 transcription factor, also known as Krox-24, is a zinc
finger transcription factor originally identified as an early
response gene that is rapidly stimulated by mitogenic and
stress stimuli [36]. The specific DNA binding site for Egr-1
is GC-rich and present within the promoter regions of a
large number of target genes important for proliferation,
differentiation, apoptosis, growth control, and inflamma-
tion [24,37-40]. Egr-1 null mice showed impairment of en-
dochondral bone repair [21,22]. In our studies, the effect
of Egr-1 on the ACVR1 promoter was clearly cell context-
dependent. Egr-1 showed no effect on the 2.9 kb promoter
sequence in ATDC5 cells and strong activation in HeLa
cells. However, Egr-1 inhibited expression from the short
72 bp basal promoter sequence in U2OS, ATDC5 and
C2C12 cells, with no effect in HeLa cells.
The ZBTB7A gene encodes the Leukemia/lymphoma-
related factor (LRF, also called Pokemon, a member of
the POK (POZ/BTB and Krüppel) family of transcrip-
tional repressors [41]. This factor has been mainly stud-
ied for roles in several types of cancer [25] as well as in
lymphocyte differentiation in the hematopoietic system
[25,26]. ZBTB7A was also studied in the skeletal systemas an osteoclast-specific protein [23]. ZBTB7A inhibited
ACVR1 in ATDC5 cells, which was an expected find-
ing given many reports that describe its action as a tran-
scriptional repressor. However, it was surprising to
observe a strong activating effect in HeLa cells.
We found that a short sequence within the first 72 bp
upstream of the ACVR1 TSS, displayed readily detectable
transcriptional activity. This region is a GC-rich sequence
which, as in other TATA-less promoters like ACVR1, is as-
sociated with transcription initiation. As expected for a
functionally important region, a high degree of conserva-
tion among species around the +1 TSS is observed.
Based on consensus sequences for conserved binding
elements, the Sp1 transcription factor and other GC
binding proteins were predicted to bind and affect the
72 bp region reporter activity.
Our transfection experiments support a role for Sp1,
although Sp1 appears to induce different degrees of acti-
vation in the various cell lines examined. The highest re-
sponse was in C2C12 cells, suggesting that the Sp1
transcription factor participates not only at the level of
minimal promoter functionality but also in cell-type re-
lated functions. One possible explanation may be due to
cooperative effects of Sp1 with other factors that bind
GC-rich sequences. Among these factors, we observed a
cell type activating effect on the ACVR1 basal promoter
by another member of the Egr family, the Egr-2/Krox20
transcription factor. This finding is of particular interest
due to the implication of Egr-2 in many processes such
as bone metabolism [42,43], immune response, inflam-
mation and monocytic/macrophagic differentiation that
are critical in FOP pathophysiology [42-44].
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raised the question of its possible ability to include a
BMP responsive element [33] which is itself a GC-rich
sequence. Our experiments did not show response to
BMP2 by the 72 bp promoter region, although the 2.9 kb
ACVR1 promoter was activated by BMP2 treatment and
can be attributed to the presence of BREs in regions up-
stream of the short minimal promoter.
Our results highlight cell-type specific functional fea-
tures in the ACVR1 gene regulation. Further investigations
will be necessary to understand which transcriptional reg-
ulators play specific roles in various cell types and bio-
logical processes, as well as to also understand their utility
in addressing new therapeutic approaches.
Conclusions
The ultimate goal of research on a rare disease such as
FOP is the development of a specific treatment that might
efficiently prevent or even reverse the occurrence of dis-
ease flare-ups and their devastating consequences. Discov-
ery of the causative gene represented a milestone in the
process of understanding the genetic and molecular basis
of FOP. Many approaches are currently being pursued to
achieve proof of principle for developing specific thera-
peutic tools. Some strategies are aimed at specifically si-
lencing the mutated allele, while others are aimed at
identifying molecules that inhibit the activity of the pro-
tein, or to target downstream signaling (see for references
and comments [2]) [45-48].
Any intervention able to restrain heterotopic bone for-
mation and/or its inciting events will benefit patients’
quality of life. Therefore, the knowledge of mechanisms
and factors that control gene function and regulation have
great potential to add an important piece to the FOP
pathogenesis puzzle.
The characterization of the ACVR1 gene promoter has
determined that this gene is potently regulated at the tran-
scriptional level and that such regulation is significantly
dependent on the cellular context. The identification of
two essential regions of the ACVR1 promoter suggests
several hypotheses related to the FOP pathogenic mech-
anism. In particular, the cell types that are involved in the
disease certainly include multipotent progenitors that can
differentiate to chondrocytes and osteoblast but also in-
clude cells of the inflammatory and immune-mediated
processes that trigger the acute phases of the disease and
stimulate osteogenesis. In patients, each of these cell types
carry the mutated receptor which is likely to exert effects
at different steps of the pathogenic mechanism and then
on the full FOP clinical picture. For this reason, we believe
that this study is a good starting point to define the
ACVR1 gene regulation in different steps of the disease
and to provide useful information on possible targets for
potential treatment strategies.Additional files
Additional file 1: Figure S1. ENCODE (Encyclopedia of DNA Elements)
data in the ACVR1 promoter region. Track from the UCSC Genome
Browser showing the ChIP-Seq data from the ENCODE Project (window
coordinates, chr2:158732343-158735255) in the 2.9 kb genomic region of
the ACVR1 promoter. The black line with numbers (with the arrow
specifying the orientation of the ACVR1 gene), and the red vertical
dashed lines have been added to indicate the positions of the reporter
construct boundaries (bPr, basal 72-bp Promoter; Pr-0.3, Pr-0.7, Pr-1.2, Pr-1
.4 and Pr-2.9). The localization patterns along the ACVR1 promoter region
of the different transcription factors listed on the right side are shown as
rectangles of different color intensity. The transcription factors studied in
this work are underlined.
Additional file 2: Figure S2. Mithramycin effect on endogenous ACVR1
mRNA expression. ACVR1 mRNA expression level was evaluated by RT-
qPCR in U2OS and C2C12 cells, both in basal conditions or upon
treatment with mithramycin A at 200 (M200) and 300 nM (M300) final
concentration. Values were normalized to the expression level of GAPDH
and β-Actin genes. Error bars indicate the standard errors of three
independent experiments.
Additional file 3: Figure S3. Effects of Egr-1 and Egr-2 on basal
promoter regulation. U2OS, HeLa, C2C12 and ATDC5 cells were co-
transfected with the Pr-0.072 reporter construct and expression vectors
carrying the Egr-1 (upper panel) or Egr-2 (bottom panel) cDNAs or the
corresponding empty vector. Observed Luciferase activity is expressed as
relative to the activity of the Pr-0.072 construct co-transfected with the
empty vector (ev). The data represent the means ± SD (error bars) of
three independent experiments carried out in triplicate with p < 0.05*,
p < 0.01**, or p< 0.001***.
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